Lung cancer assay kit LCMME02

for genetic mutationsfor genesreal-time

Real-time PCR assay to detect exon 14 skipping mutation in the MET gene Exon 14 skipping results in the deletion of the juxtamembrane domain, which leads to enhanced signaling through the MET receptor pathway. MET exon 14 skipping mutation are found in 3~4% of lung cancer patients with both the presence and absence of MET amplification. Tumors harboring MET with exon 14 skipping and/or MET amplifications have increased sensitivity to MET inhibitors, such as Crizotinib and Cabozantinib. Assay Highlights One step tube for Reverse Transcription and Real-Time PCR Results in 90 minutes Positive and Negative controls Internal control included CE-IVD GMP-compliant manufacturing ISO13485-certified laboratory Sensitivity 500 copies Specificity:100% Sample: FFPE tissues 2 fluorescent channels: FAM, HEX/VIC Mutation detected: exon 14 skipping